Re: Revised target market, indications, market potential? ... and some numbers?
|
11
|
Resverlogix Corp.
|
Jun 15, 2020 10:34AM
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
3
|
Resverlogix Corp.
|
Jun 15, 2020 02:42PM
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
7
|
Resverlogix Corp.
|
Jun 13, 2020 09:55AM
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
3
|
Resverlogix Corp.
|
Jun 13, 2020 11:27AM
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
6
|
Resverlogix Corp.
|
Jun 14, 2020 02:25AM
|
Re: Revenue Canada
|
3
|
Resverlogix Corp.
|
Nov 15, 2019 08:45AM
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
4
|
Resverlogix Corp.
|
Jul 08, 2019 09:29AM
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
5
|
Resverlogix Corp.
|
Jul 08, 2019 09:33AM
|
Re: Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
|
2
|
Resverlogix Corp.
|
Aug 14, 2019 11:22AM
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
1
|
Resverlogix Corp.
|
Dec 02, 2019 09:08AM
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
4
|
Resverlogix Corp.
|
Dec 02, 2019 10:08AM
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
8
|
Resverlogix Corp.
|
Nov 02, 2020 07:06PM
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
6
|
Resverlogix Corp.
|
Jun 22, 2020 09:50AM
|
Re: Resverlogix Provides Update on BETonMACE Phase 3 Trial
|
1
|
Resverlogix Corp.
|
Sep 16, 2019 09:07AM
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
2
|
Resverlogix Corp.
|
Nov 01, 2021 10:19AM
|
Re: Resverlogix Expands Phase 2b Clinical Trial for COVID-19
|
7
|
Resverlogix Corp.
|
Feb 17, 2022 02:43PM
|
Re: Resverlogix Confirms Significant Corporate Advancement Establishing Apabetalone as Potential Blockbuster Combo Drug in High-risk Diabetics with CVD
|
4
|
Resverlogix Corp.
|
Jan 13, 2020 09:24AM
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 27, 2020 11:05AM
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 27, 2020 02:11PM
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
2
|
Resverlogix Corp.
|
Jun 22, 2022 01:27PM
|